Cytomegalovirus glycoprotein-B vaccine with MF59 adjuvant in transplant recipients: a phase 2 randomised placebo-controlled trial

BACKGROUND: Cytomegalovirus end-organ disease can be prevented by giving ganciclovir when viraemia is detected in allograft recipients. Values of viral load correlate with development of end-organ disease and are moderated by pre-existing natural immunity. Our aim was to determine whether vaccine-in...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffiths, Paul D, Stanton, Anna, McCarrell, Erin, Smith, Colette, Osman, Mohamed, Harber, Mark, Davenport, Andrew, Jones, Gareth, Wheeler, David C, O'Beirne, James, Thorburn, Douglas, Patch, David, Atkinson, Claire E, Pichon, Sylvie, Sweny, Paul, Lanzman, Marisa, Woodford, Elizabeth, Rothwell, Emily, Old, Natasha, Kinyanjui, Ruth, Haque, Tanzina, Atabani, Sowsan, Luck, Suzanne, Prideaux, Steven, Milne, Richard SB, Emery, Vincent C, Burroughs, Andrew K
Formato: Texto
Lenguaje:English
Publicado: Lancet Publishing Group 2011
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3075549/
https://www.ncbi.nlm.nih.gov/pubmed/21481708
http://dx.doi.org/10.1016/S0140-6736(11)60136-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3075549/
https://www.ncbi.nlm.nih.gov/pubmed/21481708
http://dx.doi.org/10.1016/S0140-6736(11)60136-0

Ejemplares similares